Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 4/20 | 0.31 |
| ▸ | LDHB | P07195 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881118 | 0.85 | LDHA (0.34) | P2RX3CSNK2A1KDM4ELDHALDHB | |
| SCHEMBL5880951 | 0.83 | LDHA (0.36) | P2RX3CSNK2A1KDM4ELDHALDHB | |
| SCHEMBL13964131 | 0.82 | HSD17B3 (0.32) | — | |
| SCHEMBL5880698 | 0.82 | LDHA (0.30) | LDHALDHB | |
| SCHEMBL3993693 | 0.82 | CSNK2A1 (0.39) | P2RX3CSNK2A1KDM4E | |
| SCHEMBL3986455 | 0.80 | P2RX3 (0.36) | P2RX3 | |
| SCHEMBL3990838 | 0.80 | POLB (0.36) | P2RX3 | |
| SCHEMBL3992209 | 0.80 | P2RX3 (0.32) | P2RX3 | |
| SCHEMBL3988164 | 0.80 | ALDH1A1 (0.34) | LDHALDHB | |
| SCHEMBL3986864 | 0.79 | GNRHR (0.36) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | P2RX3 3763/4885CSNK2A1 1399/4885KDM4E 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.